Danaher Corporation Stock Price, News & Analysis

Danaher (NYSE:DHR) has appointed Greg Milosevich as Executive Vice President of its Life Sciences business, effective July 1, 2025. Milosevich, who has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021, will become an executive officer while continuing to report to CEO Rainer Blair.

Milosevich joined Danaher in 2010 through the Molecular Devices acquisition and has overseen multiple companies including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a physics degree from the University of Puget Sound.

Danaher Corporation (NYSE: DHR) has scheduled its second quarter 2025 earnings conference call for Tuesday, July 22, 2025, at 8:00 a.m. ET. The hour-long call will cover the company's financial performance and future outlook. Investors can access the webcast and slide presentation through Danaher's website under the "Investors" section. U.S. participants can dial 800-245-3047, while international callers should use +1 203-518-9765 (Conference ID: DHRQ225). The earnings press release, webcast slides, Form 10-Q, and other financial materials will be available on the website at 6:00 a.m. ET on the call date. A replay will be accessible until August 5, 2025.

SCIEX, a Danaher Corporation subsidiary, has formed a reseller agreement with Evosep Biosystems to co-sell SCIEX mass spectrometry systems with the new Evosep Eno for standardized high-throughput proteomics. The collaboration aims to provide pharmaceutical and biotech researchers with improved proteomics workflows. Research shows the Evosep Eno delivers over 5x increase in peptide precursor identifications and 3x increase in protein group identifications when paired with the ZenoTOF 8600 system. The agreement covers 19 countries across North America and Europe, with SCIEX managing customer relationships while Evosep provides UHPLC service support. This partnership enhances accessibility to advanced proteomics technology and standardized solutions.

SCIEX, a Danaher Corporation subsidiary, has launched the ZenoTOF 8600 system at ASMS 2025, establishing new benchmarks in accurate mass quantitation. The system features significant improvements including 10x better sensitivity compared to the ZenoTOF 7600+ system, enhanced ion transmission through OptiFlow Pro source and ion guides, Mass Guard technology for contamination protection, and ZT Scan DIA 2.0 for expanded mass range coverage. The launch includes SCIEX OS software version 4.0 and new collaborations with MS-Dial for metabolomics analysis and PEAKS Studio 13 for proteomics workflows, enabling more comprehensive and efficient data analysis capabilities.

SCIEX, a Danaher Corporation subsidiary, announces three major software ecosystem enhancements at ASMS. The company introduces SCIEX OS 4.0, compatible with Windows 11, featuring improved operability, advanced hardware support for the new ZenoTOF 8600 system, and enhanced security features. The second innovation, AI Quantitation software, leverages artificial intelligence to automate data processing and fragment prediction in ADME workflows, reducing manual workload and operator bias. Lastly, SCIEX MS Data Converter 2.0 supports the open-source community by improving data accessibility and processing capabilities. These updates aim to streamline laboratory operations, accelerate research, and enhance data integrity across scientific workflows.

Danaher (NYSE: DHR) has announced a strategic partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize advanced diagnostic tools for precision medicine. The collaboration will leverage Danaher's Centers for Enabling Precision Medicine and technology from its subsidiary, Leica Biosystems, focusing initially on digital and computational pathology products with AI-assisted algorithms.

The partnership aims to create diagnostic tests that help identify patients most likely to benefit from targeted therapies. Leica Biosystems will utilize its global laboratory network to deploy these tests worldwide, supported by its commitment to open-access DICOM standards for enhanced workflow connectivity.

Aldevron and Integrated DNA Technologies (IDT), both Danaher (NYSE: DHR) subsidiaries, have achieved a groundbreaking milestone by manufacturing the world's first personalized CRISPR gene editing drug to treat an infant with urea cycle disorder (UCD). The therapy was developed in just six months, three times faster than standard timelines.

The treatment, created in collaboration with Children's Hospital of Philadelphia and the University of Pennsylvania, required a new guide RNA sequence, mRNA-encoded base editor, custom off-target safety services, and clinically validated lipid nanoparticle formulation. The results were published in The New England Journal of Medicine, demonstrating the potential for safe and effective personalized CRISPR therapies.

This achievement aligns with the Danaher-IGI Beacon for CRISPR Cures initiative launched in January 2024, which aims to develop platform approaches for gene-editing medicines targeting hundreds of diseases.

Danaher Corporation (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas on May 15, 2025 at 10:00 a.m. PT. The presentation will be available via simultaneous webcast on the company's website at www.danaher.com.

Danaher Corporation (NYSE: DHR) has declared a regular quarterly cash dividend of $0.32 per share of common stock. The dividend will be paid on July 25, 2025 to shareholders who are recorded as holders on June 27, 2025. This announcement represents the company's commitment to returning value to shareholders through consistent dividend payments.